



# Synthesis of the pentasaccharide hapten from the glycopeptidolipid antigen of *Mycobacterium avium* serovar 17

Zsolt Varga,<sup>a</sup> István Bajza,<sup>b</sup> Gyula Batta<sup>c</sup> and András Lipták<sup>a,b,\*</sup>

<sup>a</sup>Department of Biochemistry, University of Debrecen, PO Box 55, Debrecen H-4010, Hungary

<sup>b</sup>Research Group for Carbohydrates of the Hungarian Academy of Sciences, PO Box 55, Debrecen H-4010, Hungary

<sup>c</sup>Research Group for Antibiotics of the Hungarian Academy of Sciences, PO Box 70, Debrecen H-4010, Hungary

Received 2 May 2001; revised 18 May 2001; accepted 31 May 2001

**Abstract**—Effective synthesis of the pentasaccharide hapten from the glycopeptidolipid antigen of *Mycobacterium avium* serovar 17 in a *p*-aminophenyl linker-containing form, using 3+2 block synthesis strategy, is described. A 2+3 block synthesis could not be achieved, although different glycosyl donors (1-Br, 1-SPh, 1-*O*-C(NH)CCl<sub>3</sub>) were used. © 2001 Elsevier Science Ltd. All rights reserved.

Besides *Mycobacterium tuberculosis*<sup>1</sup> and *M. leprae*,<sup>2,3</sup> the pathogenic agents of human tuberculosis and leprosy, respectively, another ‘atypical’ mycobacteria may also cause infections in humans.<sup>4</sup> Infections with the *M.*

*avium* serocomplex show up in more than 50% of patients with AIDS in some areas of the world.<sup>5–7</sup> This observation initiated a series of investigations, (i) to determine the surface antigens of different human




Figure 1.

**Keywords:** oligosaccharide; block synthesis; *M. avium* serovar 17; nilic acid; hapten; linker.


\* Corresponding author. Tel.: +36-52-512-913; fax: +36-52-512-913; e-mail: liptaka@tigris.klte.hu

pathogenic mycobacteria, and (ii) to prepare artificial antigens for the serodiagnosis of mycobacterial infections.<sup>8,9</sup>


In this paper we present an effective synthesis of a *p*-aminophenyl linker-containing pentasaccharide which was identified as the GPL type antigen<sup>8,9</sup> of *M. avium* serovar 17 (Fig. 1). The terminal monosaccharide unit in this structure is a 3-amino-3,6-dideoxy- $\beta$ -D-glucopyranoside<sup>10</sup> acylated with 3-hydroxy-2-methylbutyric acid (nilic acid<sup>11</sup>) at position 3. Nilic acid has two chiral centers and exists in four isomeric forms. We report here the synthesis of the (2*S*,3*S*) isomer containing pentasaccharide hapten.

For the preparation of the target pentasaccharide using a 2+3 block synthesis, we proceeded as follows. Acetolysis of 3-azido-3-deoxy-1,2-*O*-isopropylidene-6-*O*-(*p*-toluenesulfonyl)- $\alpha$ -D-glucofuranose<sup>12</sup> **1** gave an anomeric mixture of the tri-*O*-acetyl derivative **2**. Deoxygenation of **2** at position 6, leaving the 3-azido group untouched, was performed with the NaCNBH<sub>3</sub>/NaI reagent in HMPT<sup>13</sup> yielding **3** (73%). Compound **3** itself is a glycosyl donor but with low reactivity, therefore, it was transformed into the glycosyl trichloroacetimidate **4** according to the procedure of Schmidt et al.<sup>14</sup> (Scheme 1).


The TMSOTf-mediated coupling of the trichloroacetimidate **4** with phenyl 2-*O*-benzyl-4-*O*-methyl-1-thio- $\alpha$ -L-rhamnopyranoside **5** as the glycosyl acceptor



**Scheme 1.** (a) 0.1 M H<sub>2</sub>SO<sub>4</sub>, 60°C, then Ac<sub>2</sub>O/pyridine, 90%; (b) NaCNBH<sub>3</sub>, NaI, HMPT, 70°C, 73%; (c) H<sub>2</sub>NNH<sub>3</sub>OAc, DMF, rt, then CCl<sub>3</sub>CN, K<sub>2</sub>CO<sub>3</sub> CH<sub>2</sub>Cl<sub>2</sub>, rt, 85%.



**Scheme 2.** (a) TMSOTf, CH<sub>2</sub>Cl<sub>2</sub>, -50°C, 75%; (b) Br<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0°C; (c) NBS, acetone-H<sub>2</sub>O, 0°C, then CCl<sub>3</sub>CN, K<sub>2</sub>CO<sub>3</sub> CH<sub>2</sub>Cl<sub>2</sub>, rt, 75%.




**Figure 2.**

afforded exclusively the  $\beta$ -disaccharide **6** in 75% yield (Scheme 2).


However, in contrast to our expectation, the disaccharide donor **6** did not react with the trisaccharide acceptor **9** (Fig. 2), and thus to enhance its reactivity, thioglycoside **6** was transformed into the bromosugar **7** and the trichloroacetimidoyl derivative **8** (Scheme 2). However, neither **7** nor **8** reacted sufficiently, probably due to the extremely low nucleophilicity of the trisaccharide acceptor.

The unusual behavior of **9** forced us to change the original synthetic route to a 3+2 approach. Thus, the disaccharide donor **8** was reacted with ethyl 2,4-di-*O*-benzyl-1-thio- $\alpha$ -L-rhamnopyranoside **10** in the presence of TMSOTf to give the trisaccharide block **11** in a yield of 55%. The sterically 'mismatched' situation in this glycosylation led to a relatively low yield of coupling. The thioglycoside donor **11** was then allowed to react with the disaccharide acceptor **12** in the presence of NIS/TfOH to furnish the desired pentasaccharide **13** in a 69% yield (Scheme 3). Although glycosylations were performed with donors having non-participating group at C-2, in both reactions the formation of an  $\alpha$ -1,2-*trans* linkage was observed exclusively.

To avoid a possible *O*→*N* acetyl migration, the two isolated *O*-acetyl groups were removed with KO<sup>t</sup>Bu,<sup>15</sup> prior to the reduction of the azide, to obtain the diol **14**. It is to be noted, that in accord with other literature examples, removal of the hindered or isolated *O*-acetyl protecting groups by the classical Zemplén procedure



**Scheme 3.** (a) TMSOTf, CH<sub>2</sub>Cl<sub>2</sub>, –60°C, 55%; (b) NIS/TfOH, CH<sub>2</sub>Cl<sub>2</sub>–THF, –50°C, 69%; (c) KO<sup>t</sup>Bu, dioxane–MeOH, rt, quant.; (d) Ph<sub>3</sub>P, THF, 87%; (e) (2*S*,3*S*)-nilic acid, BOP/DIPEA, 72%; (f) H<sub>2</sub>/Pt, EtOAc, rt, then Py, TFA–anhydride 0°C, 78%.



**Scheme 4.** (a) H<sub>2</sub>/Pd–C, MeOH–H<sub>2</sub>O (5:1), 85%.

failed in this case.<sup>16</sup> For the effective, selective reduction of the azido group in the presence of the *p*-nitrophenyl aglycone, Ph<sub>3</sub>P<sup>17</sup> was used. The resulting amine **15** was acylated with (*S*)-3-hydroxy-(*S*)-2-methylbutyric acid (prepared from ethyl (*S*)-3-hydroxybutyrate<sup>11,18</sup>) using BOP/DIPEA as the coupling reagents. Pentasaccharide **16** was deprotected as follows. The aromatic nitro group was reduced with Adam's catalyst and the

product was converted into the trifluoroacetamido derivative **17**. Finally, the benzyl and benzylidene functions were cleaved by hydrogenolysis in the presence of Pd–C catalyst to furnish the target pentasaccharide **18**<sup>†</sup> (Scheme 4). Complete NMR data (CD<sub>3</sub>OD, BRUKER DRX 500) of **18** are given in Table 1.

The conjugation of the spacer-armed pentasaccharide hapten to protein, and the biological testing of the neoglycoconjugate are in progress and will be reported elsewhere.

<sup>†</sup> MALDI-TOF for pentasaccharide C<sub>44</sub>H<sub>67</sub>F<sub>3</sub>N<sub>2</sub>O<sub>23</sub>+Na<sup>+</sup>: 1072.54.

**Table 1.** NMR data of pentasaccharide **18** ( $\delta$ , ppm)

| Residue    |                                 | $^1\text{H}$ | $^{13}\text{C}$ |
|------------|---------------------------------|--------------|-----------------|
| A          | 1                               | 5.64         | 98.3            |
|            | 2                               | 4.03         | 77.4            |
|            | 3                               | 4.10         | 70.6            |
|            | 4                               | 3.63         | 72.6            |
|            | 5                               | 3.89         | 68.1            |
|            | CH <sub>3</sub>                 | 1.23         | 15.8            |
|            | <i>p</i> -subst. aromatic       | 7.13, 7.60   |                 |
| B          | 1                               | 5.04         | 103.4           |
|            | 2                               | 4.09         | 66.4            |
|            | 3                               | 3.81         | 77.6            |
|            | 4                               | 3.59         | 72.1            |
|            | 5                               | 3.83         | 69.5            |
|            | CH <sub>3</sub>                 | 1.31         | 17.1            |
| C          | 1                               | 5.07         | 102.7           |
|            | 2                               | 4.07         | 70.8            |
|            | 3                               | 3.88         | 78.9            |
|            | 4                               | 3.56         | 72.2            |
|            | 5                               | 3.88         | 70.1            |
|            | CH <sub>3</sub>                 | 1.29         | 17.1            |
| D          | 1                               | 5.02         | 102.6           |
|            | 2                               | 4.17         | 71.2            |
|            | 3                               | 4.06         | 79.2            |
|            | 4                               | 3.24         | 82.6            |
|            | 5                               | 3.88         | 68.1            |
|            | CH <sub>3</sub>                 | 1.28         | 16.9            |
|            | OCH <sub>3</sub>                | 3.58         | 60.5            |
| E          | 1                               | 4.63         | 104.6           |
|            | 2                               | 3.37         | 72.6            |
|            | 3                               | 3.78         | 58.1            |
|            | 4                               | 3.12         | 74.3            |
|            | 5                               | 3.39         | 73.7            |
|            | CH <sub>3</sub>                 | 1.30         | 17.0            |
| Nilic acid | C <sub>2</sub> -H               | 2.33         | 49.0            |
|            | C <sub>3</sub> -H               | 3.32         | 48.3            |
|            | C <sub>2</sub> -CH <sub>3</sub> | 1.14         | 13.6            |
|            | C <sub>3</sub> -CH <sub>3</sub> | 1.22         | 19.8            |

**Acknowledgements**

The authors would like to thank the Howard Hughes Medical Institute and the National Research Foundation (OTKA T035128) for financial support.

**References**

1. Daffé, M.; Lacave, C.; Lanéeelle, M.-A.; Lanéeelle, G. *Eur. J. Biochem.* **1987**, *167*, 155–160.
2. Hunter, S. W.; Brennan, P. J. *J. Bacteriol.* **1981**, *147*, 728–735.
3. Hunter, S. W.; Fujiwara, T.; Brennan, P. J. *J. Biol. Chem.* **1982**, *257*, 15072–15078.
4. Wolinsky, E. *Am. Rev. Respir. Dis.* **1979**, *119*, 107–159.
5. Wolinsky, E.; Schaefer, W. B. *Int. J. Syst. Bacteriol.* **1973**, *23*, 102–183.
6. Good, R. C. *Annu. Rev. Microbiol.* **1985**, *39*, 347–369.
7. Blaser, M. J.; Cohn, D. L. *Rev. Infect. Dis.* **1986**, *8*, 21–30.
8. Lipták, A.; Borbás, A.; Bajza, I. *Med. Res. Rev.* **1994**, *14*, 307–352.
9. Aspinall, G. O.; Chatterjee, D.; Brennan, P. J. *Adv. Carbohydr. Chem. Biochem.* **1995**, *51*, 169–242.
10. Richardson, C. A. *J. Chem. Soc.* **1962**, 2758–2760.
11. Jiang, Z.-H.; Geyer, A.; Schmidt, R. R. *Angew. Chem., Int. Ed. Engl.* **1995**, *34*, 2520–2524.
12. Gurjar, M. K.; Patil, V. J.; Pawar, S. M. *Indian J. Chem., Sect. B.* **1987**, *26*, 1115–1120.
13. Kuzuhara, H.; Sato, K.; Emoto, S. *Carbohydr. Res.* **1975**, *43*, 293–298.
14. Schmidt, R. R.; Michel, J. *Angew. Chem.* **1980**, *92*, 763–764.
15. Spijker, N. M.; Westerduin, P.; van Boeckel, C. A. A. *Tetrahedron* **1992**, *30*, 6297–6316.
16. Lipták, A.; Szurmai, Z.; Nánási, P.; Neszmélyi, A. *Carbohydr. Res.* **1982**, *99*, 13–21.
17. Kiso, M.; Furui, H.; Ishida, H.; Hasegawa, A. *J. Carbohydr. Chem.* **1996**, *15*, 1–14.
18. Fratèr, G.; Müller, U.; Günther, W. *Tetrahedron* **1985**, *40*, 1269–1277.